Jefferies Financial Group Inc. Makes New Investment in Disc Medicine, Inc. $IRON

Jefferies Financial Group Inc. acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON – Free Report) in the third quarter, Holdings Channel reports. The fund acquired 10,795 shares of the company’s stock, valued at approximately $707,000.

Other institutional investors have also made changes to their positions in the company. State of Wyoming bought a new stake in Disc Medicine in the second quarter valued at about $25,000. Allworth Financial LP acquired a new position in Disc Medicine in the second quarter worth about $46,000. Sterling Capital Management LLC raised its position in Disc Medicine by 842.4% in the third quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock worth $61,000 after purchasing an additional 834 shares in the last quarter. Nykredit A S acquired a new position in Disc Medicine in the second quarter worth about $103,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in Disc Medicine during the third quarter worth about $119,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Kevin Bitterman sold 25,519 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $80.23, for a total transaction of $2,047,389.37. Following the completion of the sale, the director owned 12,991 shares of the company’s stock, valued at approximately $1,042,267.93. This trade represents a 66.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William Savage sold 16,035 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $85.09, for a total transaction of $1,364,418.15. Following the sale, the insider directly owned 63,445 shares of the company’s stock, valued at approximately $5,398,535.05. The trade was a 20.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 150,277 shares of company stock valued at $11,877,059. 3.76% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IRON shares. Cantor Fitzgerald lifted their price objective on Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, October 19th. Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. HC Wainwright increased their target price on Disc Medicine from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Friday, November 6th. BMO Capital Markets raised their target price on Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Thursday, October 15th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average target price of $124.18.

View Our Latest Analysis on IRON

Disc Medicine Price Performance

IRON opened at $80.00 on Monday. The firm’s 50-day simple moving average is $71.60 and its 200-day simple moving average is $71.07. The company has a debt-to-equity ratio of 0.10, a quick ratio of 20.30 and a current ratio of 20.30. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The firm has a market cap of $3.64 billion, a price-to-earnings ratio of -12.62 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.10. Equities research analysts anticipate that Disc Medicine, Inc. will post -6.20 EPS for the current fiscal year.

About Disc Medicine

(Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON – Free Report).

Institutional Ownership by Quarter for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.